Biogeneration Ventures
© BioGeneration 2010 All rights reserved
Home
About Us
Strategy
Investment Criteria
Team
Investments
News
Contact Us
Investments

argen-x

 

 


Novel platform for the generation of human monoclonal antibodies

arGEN-X BV
Tim Van Hauwermeiren MSc, CEO
Dr Molewaterplein 50,
3015 GE Rotterdam,
The Nederlands
T: +31 6 122 85 257




logo-bioceros-2

 

Biopharmaceutical R&D contract organization and developer of anti-inflammatory and anti-cancer drugs

Bioceros BV
Bram Bout PhD, CEO
Yalelaan 46
3584 CM Utrecht, The Netherlands
T: +31 (0)30 - 2537910




   flexgen

 

 

Commercialization of a fast and flexible custom microarray synthesis instrument for genomic selection in next generation sequencing and other applications.

FlexGen BV

Fred Dom MSc., CEO
Wassenaarseweg 72
2333 AL Leiden, The Netherlands
T: +31 71 332 22 00




medisse-logo

  

 

Biomaterials company developing resorbable medical implants based on proprietary polymers

Medisse BV
Sandra de Vos
Barchman Wuytierslaan 154
3818 LM Amersfoort, The Netherlands
T: + 31 (0)650 281 838




mucosis

 

 

Developer of vaccines based on proprietary adjuvant and carrier technology

Mucosis BV
Govert Schouten PhD, CEO
L. J. Zielstraweg 1
9713 GX Groningen, The Netherlands
T: +31 (0)50 3612112

 



noviogendix-logo

  


Service Lab for molecular diagnostics and research in biomarkers for GU cancer

NovioGendix BV
Bastiaan J. de Leeuw, CEO
Geert Grooteplein-Zuid 10
6525 GA Nijmegen, The Netherlands
T: + 31 (0)24 3279054




 progentix-logo

 

 
Unique osteoinductive materials for clinical application in bone regenerative surgery

Progentix Orthobiology BV
Joost D. de Bruijn PhD, CEO
Prof. Bronkhorstlaan 10-d
3723 MB Bilthoven, The Netherlands